BioVie
Manufacturing · Nevada, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
680 W Nye Ln Ste 204, Carson City, Nevad...Phone Number
(775) 888-3162Website
www.bioviepharma.comRevenue
<$5 MillionStock Symbol
BIVIIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About BioVie
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Explore more
BioVie Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioVie your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when BioVie launches new products
Congratulate Masked Content for being promoted to Masked Content at BioVie
Check out if BioVie is spiking on competitors!
Funding: Get notified immidiatlly once BioVie has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BioVie has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on BioVie recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if BioVie had a recent Job posting/layoffs
BioVie, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at BioVie
Find 3 more new buyers
Compare Similar Companies to BioVie
Compare insights from companies similar to BioVie, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioVie is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioVie is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioVie.
BioVie financials insights
Gather financial insights about BioVie, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$16M
2024
Private Equity
$18.8M
Grant
$12.6M
BioVie Tech Stack
A closer look at the technologies used by BioVie
Most Recent Scoops
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Project
BioVie has reported that its Long COVID trial is enrolling rapidly with one academic site still in final activation stages, expecting full enrollment by the end of February 2025 and top-line data readout in summer 2025.
Medical Research, Pharmaceuticals, Clinical Operations
Project
BioVie has planned phase III program for Parkinson's will consist of two parts: a short three to six-month study demonstrating symptomatic relief, followed by an open-label study for another year to demonstrate disease modification.
Medical Research, Pharmaceuticals, Clinical Operations
Project
BioVie has announced that its preclinical studies demonstrated that the combination of bezisterim and levodopa dramatically reduced the incidence of dyskinesia compared to levodopa alone.
Research & Development, Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals, Clinical Operations
BioVie News & Media
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m. ET.BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
-Topline Data Release Targeted Late Summer 2026-BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026 Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioVie
Sign Up For FreeTo access detailed company insights
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis;... Read More
